Tyson V. Sharp

Tyson V. Sharp is a Professor of Cellular and Molecular Biology serving as Centre Lead, Group Leader, and Research Theme Lead at the Centre for Cancer Cell and Molecular Biology. His academic credentials include a BSc (Hons) and PhD, establishing his foundation in molecular oncology research.

Dr. Sharp's research program centers on unraveling cancer's molecular complexities with particular emphasis on the LIMD1 protein's critical roles in cell cycle regulation, tumor suppression, and hypoxia response. His multidisciplinary approach integrates molecular virology, immuno-oncology, and microRNA biology to develop innovative preclinical models for identifying novel therapeutic targets. This work bridges fundamental molecular mechanisms with translational applications aimed at improving cancer patient outcomes through targeted therapies.

His research portfolio demonstrates significant funding success including:

• Barts Charity grant (2024-2027): 'Deciphering the Mechanisms Governing Response to Immune Checkpoint Blockade in BRCA mutant Ovarian Cancer' (£271,675)
• Prostate Cancer UK Research Innovation Award (2023-2026): 'Understanding and exploiting the PTEN driven alternative splicing programme in hypoxic prostate tumours' (£275,357)
• Breast Cancer Now project grant (2023-2026): 'Defining a new breast cancer tumour suppressor gene' (£242,000)
• Rosetrees Trust Intermediate Research Project Award (2022-2024): £51,288
• BBSRC ALERT-Equipment bid Award (2022-onwards): 'A confocal microscope for multidisciplinary dynamic studies' (£390,834, Co-PI)
• Barts Charity Seed Award (2022-2024): 'Development of a new mouse lung cancer model' (£48,256, PI)
• BBSRC Project Grant (2021-2024): 'The Lexicon of miRISC' (£633,000)

Dr. Sharp maintains active scientific leadership through editorial roles including Associate Editor positions for Frontiers in Cell and Developmental Biology and Frontiers in Oncology, Topic Editor for Cells, and editorial board membership for Scientific Reports. He regularly reviews for high-impact journals such as Oncogene, RNA, Nature Press, Journal of Molecular Medicine, PLoS Press, and Nucleic Acids Research.

His laboratory within the Centre for Cancer Cell and Molecular Biology drives research across key thematic areas including Targeting Tumour Cells, Cell Signalling, Gene Therapy, Immunotherapy, and Lung cancer. The team's work on LIMD1 molecular mechanisms has established critical connections between hypoxia pathways, microRNA regulation, and tumor suppression with direct implications for therapeutic development.